A

nd so, another workweek will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Once again, our agenda is rather modest. We plan to check in on the Pharmalot ancestors, hang with our short people, and search for the Great Pumpkin. And what about you? This remains a delightful time of year to enjoy the great outdoors. You could take a long, rambling drive somewhere or perhaps you would like to pick a few apples. Or you could simply stop to count your blessings. Well, whatever you do, have a grand time, but be safe. Enjoy, and see you soon…

A Chicago federal jury decided that AbbVie should pay more than $140 million to a man after finding the company failed to properly test its AndroGel drug for an increased risk of heart attack and misrepresenting its safety for treating a decrease in testosterone caused by age. This is the second verdict against AbbVie to emerge from more than 6,000 similar lawsuits against AbbVie and other companies consolidated in the court, Reuters notes.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy